Current criteria for the diagnosis and treatment of multiple myeloma (literature review)

Authors

  • O.O. Yamenko Bogomolets National Medical University, Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2663-3272.2.4.2019.195186

Keywords:

multiple myeloma, Bence Jones protein, M protein, high-dose chemotherapy, autologous stem cell transplantation, review

Abstract

Multiple myeloma (MM) is about 1 % of all malignancies and 10–15 % in the structure of hemoblastoses. In most patients, MM develops as a result of monoclonal gammopathy of undetermined significance, which is usually diagnosed accidentally in 3–5 % of people over 50 years of age. The average risk of MM progression is about 1 % per year. Thanks to modern diagnostic methods, the diagnosis of MM is now being established faster, which allows the treatment to be started as soon as possible. Polychemotherapy plays a leading role in the comprehensive treatment of MM. At the present stage, novel, particularly targeted, drugs are being developed, the use of which is more effective. An important place in the treatment of MM belongs to high-dose chemotherapy followed by transplantation of stem cells. Some problems in the diagnosis and treatment of patients with MM remain unresolved, so they need more detailed revision, further development of pharmacological drugs and treatment regimens, additional clinical studies. The literature review is based on clinical research data, guidelines of the European Society for Medical Oncology, National Comprehensive Cancer Network, obtained using the PubMed search resource.

References

Gerecke C., Fuhrmann S., Strifler S., Schmidt-Hieber M., Einsele H., Knop S. The Diagnosis and Treatment of Multiple Myeloma. Dtsch. Arztebl. Int. 2016 Jul 11. 113 (27-28). 470-6. doi: 10.3238/arztebl.2016.0470.

Бюлетень Національного канцер-реєстру № 20. Рак в Україні, 2017–2018. С. 68. Табл. 1.

Chavda S.J., Yong K. Multiple myeloma. Br. J. Hosp. Med. (Lond). 2017 Feb 2. 78(2). C21-C27. doi: 10.12968/hmed.2017.78.2.C21.

[Guideline] National Comprehensive Cancer Network; https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed September 6, 2019.

Rajkumar S.V., Dimopoulos M.A., Palumbo A. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014. 15. e538-e548.

Palumbo A., Avet-Loiseau H., Oliva S., Lokhorst H.M., Goldschmidt H., Rosinol L. et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J. Clin. Oncol. 2015. 33. 2863-2869.

Avet-Loiseau H., Durie B.G., Cavo M. et al. International Myeloma Working Group. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia. 2013. 27(3). 711-717.

Costa L.J., Zhang M.J., Zhong X. et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol. Blood Marrow. Transplant. 2013. 19(11). 1615-1624.

Scott K., Hayden P.J., Will A., Wheatley K., Coyne I. Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst. Rev. 2016 Apr 20. 4. CD010816. doi: 10.1002/14651858.CD010816.pub2.

Moreau P., San Miguel J., Sonneveld P., Mateos M.V., Zamagni E. et al. ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2017 Jul 1. 28 (suppl. 4). iv52-iv61. doi: 10.1093/annonc/mdx096.

Issue

Section

Young Scientist